Resistance of leukemic stem-like cells in AML cell line KG1a to natural killer cell-mediated cytotoxicity

Cancer Letters

Volumn 318, Issue 2, 2012, Pages 173-179

  She, Miaorong ^a   Niu, Xinqing ^b,f   Chen, Xilin ^c   Li, Jinggao ^d   Zhou, Maohua ^a   He, Yanjie ^b   Le, Yi ^e   Guo, Kunyuan ^b  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY   (China)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

Leukemia; Leukemic stem cell; Natural killer cell; NKG2D ligand; NOD SCID mice

Indexed keywords

CD34 ANTIGEN; CD38 ANTIGEN; LIGAND; NATURAL KILLER CELL RECEPTOR NKG2D;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CELL FUNCTION; CELL GROWTH; CELL MEDIATED CYTOTOXICITY; CELL PROTECTION; CELL RENEWAL; CELL STRAIN KG1A; CULTURE MEDIUM; FEMALE; HUMAN; HUMAN CELL; LEUKEMIC STEM CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ANTIGENS, CD34; ANTIGENS, CD38; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; NEOPLASTIC STEM CELLS;

MUS;

EID: 84858150371     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.12.017     Document Type: Article

References (41)

1. Yagi T., Morimoto A., Eguchi M., Hibi S., Sako M., Ishii E., et al. Identification of a gene expression signature associated with pediatric AML prognosis. Blood 2003, 102:1849-1856.
2. Hope K.J., Jin L., Dick J.E. Human acute myeloid leukemia stem cells. Arch. Med. Res. 2003, 34:507-514.
3. Sperr W.R., Hauswirth A.W., Florian S., Ohler L., Geissler K., Valent P. Human leukaemic stem cells: a novel target of therapy. Eur. J. Clin. Invest. 2004, 34(Suppl 2):31-40.
4. Ravandi F., Estrov Z. Eradication of leukemia stem cells as a new goal of therapy in leukemia. Clin. Cancer Res. 2006, 12:340-344.
5. Fardel O., Payen L., Courtois A., Drenou B., Fauchet R., Rault B. Differential expression and activity of P-glycoprotein and multidrug resistance-associated protein in CD34-positive KG1a leukemic cells. Int. J. Oncol. 1998, 12:315-319.
6. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
7. de Figueiredo-Pontes L.L., Pintao M.C., Oliveira L.C., Dalmazzo L.F., Jacomo R.H., Garcia A.B., et al. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia. Cytometry B Clin. Cytom. 2008, 74:163-168.
8. Ho M.M., Hogge D.E., Ling V. MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. Exp. Hematol. 2008, 36:433-442.
9. Zou G.M. Cancer stem cells in leukemia, recent advances. J. Cell. Physiol. 2007, 213:440-444.
10. Jordan C.T. The leukemic stem cell. Best Pract. Res. Clin. Haematol. 2007, 20:13-18.
11. Ruggeri L., Mancusi A., Capanni M., Urbani E., Carotti A., Aloisi T., et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007, 110:433-440.
12. Mimeault M., Batra S.K. Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers. Panminerva Med. 2008, 50:3-18.
13. Jawad M., Seedhouse C., Mony U., Grundy M., Russell N.H., Pallis M. Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. Leukemia 2010, 24:74-80.
14. Dick J.E. Acute myeloid leukemia stem cells. Ann. N. Y. Acad. Sci. 2005, 1044:1-5.
15. Chan W.I., Huntly B.J. Leukemia stem cells in acute myeloid leukemia. Semin. Oncol. 2008, 35:326-335.
16. Yang Z.F., Ngai P., Ho D.W., Yu W.C., Ng M.N., Lau C.K., et al. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 2008, 47:919-928.
17. Wu A., Oh S., Wiesner S.M., Ericson K., Chen L., Hall W.A., et al. Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties. Stem Cells Dev. 2008, 17:173-184.
18. Loebinger M.R., Giangreco A., Groot K.R., Prichard L., Allen K., Simpson C., et al. Squamous cell cancers contain a side population of stem-like cells that are made chemosensitive by ABC transporter blockade. Br. J. Cancer 2008, 98:380-387.
19. Fillmore C.M., Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 2008, 10:R25.
20. Wang J., Guo L.P., Chen L.Z., Zeng Y.X., Lu S.H. Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res. 2007, 67:3716-3724.
21. Styczynski J., Drewa T. Leukemic stem cells: from metabolic pathways and signaling to a new concept of drug resistance targeting. Acta Biochim. Pol. 2007, 54:717-726.
22. Chumsri S., Matsui W., Burger A.M. Therapeutic implications of leukemic stem cell pathways. Clin. Cancer Res. 2007, 13:6549-6554.
23. Hope K.J., Jin L., Dick J.E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat. Immunol. 2004, 5:738-743.
24. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
25. Rich J.N. Cancer stem cells in radiation resistance. Cancer Res. 2007, 67:8980-8984.
26. Jagani Z., Khosravi-Far R. Cancer stem cells and impaired apoptosis. Adv. Exp. Med. Biol. 2008, 615:331-344.
27. Raaijmakers M.H., de Grouw E.P., Heuver L.H., van der Reijden B.A., Jansen J.H., Scheper R.J., et al. Breast cancer resistance protein in drug resistance of primitive CD34 cells in acute myeloid leukemia. Clin. Cancer Res. 2005, 11:2436-2444.
28. Tallman M.S., Gilliland D.G., Rowe J.M. Drug therapy for acute myeloid leukemia. Blood 2005, 106:1154-1163.
29. +CD38-progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res. 2000, 60:4403-4411.
30. Ogbomo H., Michaelis M., Klassert D., Doerr H.W., Cinatl J. Resistance to cytarabine induces the up-regulation of NKG2D ligands and enhances natural killer cell lysis of leukemic cells. Neoplasia 2008, 10:1402-1410.
31. Zhang C., Niu J., Zhang J., Wang Y., Zhou Z., Tian Z. Opposing effects of interferon-alpha and interferon-gamma on the expression of major histocompatibility complex class I chain-related A in tumors. Cancer Sci. 2008, 99:1279-1286.
32. Jinushi M., Vanneman M., Munshi N.C., Tai Y.T., Prabhala R.H., Ritz J., et al. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc. Natl. Acad. Sci. USA 2008, 105:1285-1290.
33. Watson N.F., Spendlove I., Madjd Z., McGilvray R., Green A.R., Ellis I.O., et al. Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. Int. J. Cancer 2006, 118:1445-1452.
34. Gasser S., Orsulic S., Brown E.J., Raulet D.H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005, 436:1186-1190.
35. Butler J.E., Moore M.B., Presnell S.R., Chan H.W., Chalupny N.J., Lutz C.T. Proteasome regulation of ULBP1 transcription. J. Immunol. 2009, 182:6600-6609.
36. Bae J.H., Kim J.Y., Kim M.J., Chang S.H., Park Y.S., Son C.H., et al. Quercetin enhances susceptibility to NK cell-mediated lysis of tumor cells through induction of NKG2D ligands and suppression of HSP70. J. Immunother. 2010, 33:391-401.
37. She M., Pan I., Sun L., Yeung S.C. Enhancement of manumycin A-induced apoptosis by methoxyamine in myeloid leukemia cells. Leukemia 2005, 19:595-602.
38. She M., Yang H., Sun L., Yeung S.C. Redox control of manumycin A-induced apoptosis in anaplastic thyroid cancer cells: involvement of the xenobiotic apoptotic pathway. Cancer Biol. Ther. 2006, 5:275-280.
39. Armeanu S., Krusch M., Baltz K.M., Weiss T.S., Smirnow I., Steinle A., et al. Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma. Clin. Cancer Res. 2008, 14:3520-3528.
40. Kim J.Y., Bae J.H., Lee S.H., Lee E.Y., Chung B.S., Kim S.H., et al. Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide. J. Immunother. 2008, 31:475-486.
41. Vales-Gomez M., Chisholm S.E., Cassady-Cain R.L., Roda-Navarro P., Reyburn H.T. Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors. Cancer Res. 2008, 68:1546-1554.